Immune checkpoint inhibitors are a type of immunotherapy drugs. Targeted immune therapies are becoming conventional treatments for advanced-stage cancers, despite the fact that traditional chemotherapeutic medications remain the first-line option for most cancer types. These drugs stimulate the immune system's recognition and killing of cancer cells by targeting cell surface checkpoint proteins. The key drivers for the immune checkpoint inhibitors market are, increasing prevalence of cancer across the globe along with development of novel targeted therapies for management of cancers.
MARKET SCOPE
The "Global Immune Checkpoint Inhibitors Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the immune checkpoint inhibitors market with detailed market segmentation by type and application. The report provides key statistics on the market status of the leading immune checkpoint inhibitors market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type the market is segmented as, CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor.
- Based on application the market is segmented as, lung cancer, bladder cancer, melanoma, hodgkin lumphoma and others.
MARKET DYNAMICS
Drivers:
- Increasing prevalence of cancer across the globe along with development of novel targeted therapies for management of cancers.
- Growing healthcare expenditures, increasing rates of cancer screening procedures and technological advancements are also expected to fuel the market growth.
- Growing rates of metastatic and high grade maliganancies.
Restraints:
- However, high cost associated with the research and development activities are expected to restrain market growth during the forecast period.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The immune checkpoint inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the immune checkpoint inhibitors market in these regions.
IMPACT OF COVID-19 ON IMMUNE CHECKPOINT INHIBITORS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the immune checkpoint inhibitors market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from immune checkpoint inhibitors market are anticipated to lucrative growth opportunities in the future with the rising demand for immune checkpoint inhibitors in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the immune checkpoint inhibitors market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- AstraZeneca
- BristolMyers Squibb Company
- Lilly
- Fortress Biotech, Inc
- F. Hoffmann-La Roche Ltd
- Immutep
- Merck Sharp and Dohme Corp
- AbbVie Inc
- Novartis AG
- Pfizer Inc.